Rocbrutinib plus chemoimmunotherapy led to complete responses in patients with untreated B-cell lymphomas.
Commentary|Videos|June 16, 2024
Dr Samarasinghe on the Feasibility of First-Line Blinatumomab in Down Syndrome B-ALL
Author(s)Sujith Samarasinghe, MD
Sujith Samarasinghe, MD, discusses key results from the phase 2 ALLTOGETHER 1 DS trial in Down Syndrome B-cell acute lymphoblastic leukemia.
Advertisement
Sujith Samarasinghe, MD, consultant pediatric hematologist, Great Ormond St. Hospital, discusses key results from the phase 2 ALLTOGETHER 1 DS trial evaluating the use of first-line blinatumomab (Blincyto) as chemotherapy replacement for patients with Down Syndrome B-cell acute lymphoblastic leukemia (B-ALL) that were presented at the
Advertisement
Related to this article
The decision removes the triple-class–refractory requirement and allows melflufen use after at least 2 prior lines of therapy.
Read a refresh of hematologic cancer FDA news from October 2026, including the approval of a noncovalent BTK inhibitor in untreated CLL/SLL.
Pooled phase 1/2 data support 10 mg/kg every 3 weeks as the provisional pivotal dose of the PD-1/VEGF bispecific antibody cesalatamig in previously treated NSCLC.
A dual antigen–targeted T-cell engager doublet produced durable PSA responses in late-line metastatic castration-resistant prostate cancer.
Invikafusp alfa plus sacituzumab govitecan produced responses and disease control in metastatic TNBC and HR-positive/HER2-negative breast cancer.
A post hoc analysis of SPEARHEAD-1 found that MAGE-A4 H-score was independently tied to response and progression-free survival, whereas baseline tumor burden was tied to overall survival.
The IL-12–expressing self-replicating mRNA STX-001 showed a favorable therapeutic window at 100 µg, with regression in both injected and non-injected lesions.
Advertisement
Advertisement
Trending on OncLive
1
Cesalatamig Monotherapy Shows Dose-Dependent Activity in PD-(L)1 Inhibitor–Experienced NSCLC
2
Dr Moser on Outcomes for WTX-124 ± Pembrolizumab in Advanced Immune-Sensitive Solid Tumors
3
Dr Banks on the Feasibility of Lifileucel in Select Metastatic Sarcomas
4
BCMA-Directed Bispecifics and ADCs Broaden Treatment Sequencing Options in R/R Myeloma
5